Longeveron (LGVN) Total Liabilities (2021 - 2026)
Longeveron (LGVN) posted quarterly Total Liabilities of $5.2 million for Q1 2026, up 40.46% year-over-year from $3.7 million in Q1 2025, and up 13.02% quarter-over-quarter from $4.6 million in Q4 2025.
Longeveron (LGVN) Total Liabilities (2021 - 2026) Analysis & Trends
Longeveron's Total Liabilities history runs 6 years deep, the most recent figure standing at $5.2 million for Q1 2026.
- In Q1 2026, Total Liabilities rose 40.46% year-over-year to $5.2 million; the TTM figure through Mar 2026 stood at $5.2 million (up 40.46% YoY), while the FY2025 annual figure was $4.6 million, up 24.93% from the prior year.
- Total Liabilities for Q1 2026 stood at $5.2 million, up from $4.6 million in the prior quarter.
- The five-year high for Total Liabilities was $6.9 million in Q4 2022, with the low at $3.7 million in Q4 2024.
- The 5-year median for Total Liabilities is $5.1 million (2023), against an average of $5.1 million.
- The sharpest annual moves came in 2025 and 2026: Total Liabilities sank 44.56% in 2025, then jumped 40.46% in 2026.
- Longeveron's Total Liabilities stood at $6.9 million in 2022, then slipped by 22.76% to $5.3 million in 2023, then tumbled by 31.22% to $3.7 million in 2024, then climbed by 24.93% to $4.6 million in 2025, then climbed by 13.02% to $5.2 million in 2026.
- Business Quant data shows LGVN's Total Liabilities at $5.2 million in Q1 2026, $4.6 million in Q4 2025, and $5.6 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.62 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 4.20 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 4.00 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 3.22 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 1.35 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 10.03 Bn |
| 10 | Longeveron | 26.51 Mn | 16.41 Mn | 182,000.00 | 5.09 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 5.09 Mn |
| Mar 31, 2026 | 5.18 Mn |
| Dec 31, 2025 | 4.59 Mn |
| Sep 30, 2025 | 5.59 Mn |
| Jun 30, 2025 | 4.09 Mn |
| Mar 31, 2025 | 3.69 Mn |
| Dec 31, 2024 | 3.67 Mn |
| Sep 30, 2024 | 4.28 Mn |
| Jun 30, 2024 | 4.48 Mn |
| Mar 31, 2024 | 6.66 Mn |
| Dec 31, 2023 | 5.34 Mn |
| Sep 30, 2023 | 4.99 Mn |
| Jun 30, 2023 | 5.83 Mn |
| Mar 31, 2023 | 5.49 Mn |
| Dec 31, 2022 | 6.91 Mn |
| Dec 31, 2021 | 5.31 Mn |